Vasega Fou o Togafitiga Neuromuscular ile Psychiatry

A HOLD Fa'asa'oloto 5 | eTurboNews | eTN

O le Healis Therapeutics, o se kamupani fa'akomepiuta fa'apitoa, na fa'asalalauina i aso nei lana misiona e tu'uina atu se vasega fou o le neuromuscular therapeutics i psychiatry.

O le Kamupani Faʻavae ma le Pule Sili o Dr. Eric Finzi na faia faʻasalalauga i le lalolagi atoa ina ua ia faʻasalalau le faʻataʻitaʻiga muamua o loʻo faʻaalia ai le aoga o le botulinum toxin i le togafitia o le maʻi faʻafitauli tele (MDD) i le 2006. Mulimuli ane, e lima Vaega II faʻataʻitaʻiga faʻataʻitaʻiga ua faʻaalia ai le aoga o le botulinum toxin e pei o se togafitiga mo le atuatuvale.

O loʻo taumafai le kamupani e faʻavavevave le atinaʻeina o le botulinum toxin e avea o se togafiti togafitiga faʻapitoa mo le atuatuvale. E silia ma le 19 miliona tagata Amerika e mafatia i le atuatuvale, ma e tusa ma le 280 miliona mataupu i le lalolagi atoa, e tusa ai ma le Faalapotopotoga o le Soifua Maloloina a le Lalolagi (WHO). E ala i le tulituliloaina o auala eseese neuromuscular nai lo togafitiga o loʻo iai nei, e taumafai Healis e atiaʻe ni togafitiga fou e ono mafai ona fai. I le Vaega II su'esu'ega, o le botulinum toxin o lo'o tui i le glabellar region ma fa'afefe maso, e aofia ai le corrugator ma le procerus. O le toxin o le botulinum e manatu e togafitia le atuatuvale e ala i le faʻaogaina o foliga i le va o foliga maso ma le faiʻai.

Botulinum toxin o loʻo faʻamaonia nei e le FDA mo migraine masani, dystonia cervical, ma axillary hyperhidrosis, faʻatasi ai ma isi faʻamatalaga faafomaʻi. O le faʻateleina o le vaetamaina o le botulinum toxin i vailaʻau faʻaonaponei o loʻo tu i luga o le luasefulu tausaga o le faʻaaogaina i fale gaosi oloa.

Fa'asalaga: E o'o mai i le aso 23 Tesema 2021, o le botulinum toxin e le'o se vaila'au fa'amaonia e le FDA mo le togafitia o le ma'i fa'anoanoa tele (MDD), fa'alavelave fa'aletonu, po'o le fa'ama'i fa'ama'i pe a uma le fa'alavelave (PTSD). Botulinum toxin mo le MDD, bipolar depression, ma le PTSD o lo'o fa'aoga su'esu'e na'o le avanoa mo le tufatufaina fa'apisinisi.

OA MEA E AVEA MAI LENEI TUSI:

  • The company seeks to accelerate the development of botulinum toxin as a potential psychiatric treatment option for depression.
  • As of 23 December 2021, botulinum toxin is not an FDA approved drug for the treatment of major depressive disorder (MDD), bipolar depression, or post-traumatic stress disorder (PTSD).
  • In Phase II studies, botulinum toxin is injected in the glabellar region and frown muscles, including the corrugator and procerus.

<

E uiga i le tusitala

Linda Hohnholz

Faatonu sili mo eTurboNews fa'avae ile eTN HQ.

lesitala
Faasilasila i
mālō
0 faamatalaga
Manatu Faʻapena
Vaʻai manatu uma
0
E te alofa i ou mafaufauga, faamolemole taʻu mai.x
()
x
Fa'asoa i...